Skip to main content
Clinical Trials/ACTRN12617000816358
ACTRN12617000816358
Terminated
未知

The evaluation of the use of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans and Magnetic Resonance Imaging (MRI) to better target cancer sites for men with high-risk prostate cancer requiring high dose radiotherapy as a means to improve quality of life and clinical outcomes.

The Garvan Institute of Medical Research0 sites20 target enrollmentJune 5, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
High risk prostate cancer
Sponsor
The Garvan Institute of Medical Research
Enrollment
20
Status
Terminated
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 5, 2017
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials